CFB
ACAD icon

Cullen/Frost Bankers’s Acadia Pharmaceuticals ACAD Stock Holding History

Cullen/Frost Bankers’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.77K Hold
70
– – ﹤0.01% 1297
2026
Q1 		$1.56K Hold
70
– – ﹤0.01% 1276
2025
Q4 		$1.87K Hold
70
– – ﹤0.01% 1260
2025
Q3 		$1.49K Hold
70
– – ﹤0.01% 1244
2025
Q2 		$1.51K Hold
70
– – ﹤0.01% 1207
2025
Q1 		$1.16K Buy
+70
New +$1.27K ﹤0.01% 1213

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Cullen/Frost Bankers's ACAD Position: Q2 2026 in Review

Cullen/Frost Bankers held its Acadia Pharmaceuticals (ACAD) position steady in Q2 2026 at 70 shares worth $1.77K. The position accounts for ﹤0.01% of the portfolio, ranked #1297.

Cullen/Frost Bankers first reported a position in ACAD in Q1 2025 and has held it in 6 quarters since. The position peaked at $1.87K in Q4 2025. 354 funds tracked by Wall St. Rank hold ACAD as of Q2 2026.

  • Cullen/Frost Bankers held 70 shares of Acadia Pharmaceuticals worth $1.77K as of Q2 2026.
  • Cullen/Frost Bankers left its Acadia Pharmaceuticals share count unchanged in Q2 2026.
  • Acadia Pharmaceuticals made up ﹤0.01% of Cullen/Frost Bankers's portfolio in Q2 2026, its #1297 holding.
  • Cullen/Frost Bankers first reported a position in Acadia Pharmaceuticals in Q1 2025 and has held it in 6 quarters since.
  • Cullen/Frost Bankers's Acadia Pharmaceuticals position peaked at $1.87K in Q4 2025.
  • 354 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2026.

Based on Cullen/Frost Bankers's 13F filing for Q2 2026, filed 27 Jul 2026.